Receptors drug development

The concept of drug development is based on the findings that retinoid receptors (RARs and RXRs) offer a new approach by targeting different genes depending on the activated retinoid receptor complexes. The multiplicity of these retinoid signaling pathways affords potential for therapeutic opportunity as well as retinoid therapy associated undesired side effects. It is possible that the indiscriminate activation of all pathways by nonspecific retinoid ligands could lead to unacceptable side effects so that any enhanced efficacy would be obtained at the cost of enhanced toxicity. 

Polosa R, Holgate ST Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation. Curr Drug Targets... 

As members of the GPCR superfamily have historically dominated drug development programs, so too has interest in chemokine receptors as therapeutic targets. 

Buckley, N. J. (1990). Molecular pharmacology of cloned muscarinic receptors. In Transmembrane Signalling, Intracellular Messengers and Implications for Drug Development, ed. S. R. Nahorski, pp. 11-30. Chichester John Wiley 8r Sons. 

Pharmaceutical drug development of small molecules is initially based on the selection of candidate targets - mainly enzymes, receptors or circulating proteins that are currently targeted by 45, 28 and 11% of marketed compounds, respec-... 

Substance P, an undecapeptide, is abundant both in the periphery and in the central nervous system. It is usually co-localized with one of the classical neurotransmitters, most commonly serotonin. Substance P is thought to have a role in the regulation of pain, asthma, psoriasis, inflammatory bowel disease and, in the CNS, emesis, migraine, schizophrenia, depression and anxiety. The substance-P-preferring receptor neurokinin-1 has been focused on most intensively in drug development, and existing... 

---